Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,226
Out of 5,124 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $36.01 | +16.63% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $156.15 | +140.15% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $81.96 | +40.31% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $78.81 | +16.74% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $13.73 | -12.60% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $9.61 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $72.80 | +23.63% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $253.52 | +6.50% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $112.91 | -39.78% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $11.23 | +300.71% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $122.04 | +125.34% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $23.09 | +60.24% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $66.37 | -9.60% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $95.35 | -63.29% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $284.24 | -71.50% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $36.01
Upside: +16.63%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $156.15
Upside: +140.15%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $81.96
Upside: +40.31%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $78.81
Upside: +16.74%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $13.73
Upside: -12.60%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.61
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $72.80
Upside: +23.63%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $253.52
Upside: +6.50%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $112.91
Upside: -39.78%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $11.23
Upside: +300.71%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $122.04
Upside: +125.34%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $23.09
Upside: +60.24%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $66.37
Upside: -9.60%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $95.35
Upside: -63.29%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $284.24
Upside: -71.50%